Buzzing :

Monthly Investment GuideRBI forex swap facilityH1N1 VirusCanada Visa Wait TimeIND vs SL 2nd TestAugmont Enterprise IPOHy-Tech Engineers IPOAnti-Reservation ProtestSC on CBSE Language Policy
Home / Company / Quarterly Results / Alembic Pharmaceuticals Ltd Quarterly Results

Alembic Pharmaceuticals Ltd Quarterly Results

Q1 FY26-27 Results Summary

Revenue

The revenue stands at ₹2,149.77 crore, reflecting a quarter-on-quarter *(QoQ) increase of 16.35 per cent from ₹1,847.72 crore. This corresponds to a year-on-year *(YoY) growth of 25.66 per cent.

Operating Profit

Operating Profit stands at ₹331.86 crore, reflecting a quarter-on-quarter *(QoQ) increase of 63.35 per cent from ₹203.16 crore. This corresponds to a year-on-year *(YoY) growth of 18.14 per cent.

PBDT

PBDT stands at ₹319.57 crore, reflecting a quarter-on-quarter *(QoQ) increase of 54.23 per cent from ₹207.21 crore. This corresponds to a year-on-year *(YoY) growth of 21.10 per cent.

Profit Before Tax

Profit Before Tax stands at ₹221.86 crore, reflecting a quarter-on-quarter *(QoQ) increase of 87.03 per cent from ₹118.62 crore. This corresponds to a year-on-year *(YoY) growth of 16.70 per cent.

Net Profit

Net Profit stands at ₹172.36 crore, reflecting a quarter-on-quarter *(QoQ) decrease of 14.47 per cent from ₹201.53 crore. This represents a 12.19 per cent year-on-year *(YoY) growth for the same year.

  • YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.

Alembic Pharmaceuticals Ltd News

Alembic Pharma Q1FY27 results: Net profit rises 12% to ₹173 crore

2 min read

Alembic Pharmaceuticals gets USFDA nod for generic acne treatment gel

1 min read

Alembic Pharma gets USFDA nod for drug to treat influenza A and B in babies

2 min read

Alembic Pharma gets tentative approval from USFDA for generic cancer drug

1 min read

Alembic Pharma shares plunge 9% on soft Q4 results, weak margins drag

4 min read

Alembic Pharmaceuticals Q4 FY26 results: Net profit rises 29% at ₹202.7 cr

2 min read

Alembic Pharma gains 4% on getting USFDA nod for Dapagliflozin tablets

2 min read
More

Alembic Pharmaceuticals Ltd Earnings

CategoryQ1 FY26-27Q1 FY25-26Change %FY25-26FY24-25Change %
Total Revenue2,149.771,710.7225.667,344.906,672.0810.08
Expenses1,817.911,429.8227.146,293.435,663.8411.12
Other Income15.326.50135.6954.6656.29-2.90
Operating Profit331.86280.9018.141,106.131,064.533.91
Depreciation97.7173.7732.45318.55278.5814.35
Interest27.6123.5217.3993.6378.7718.87
Profit Before Tax221.86190.1116.70693.95707.18-1.87
Tax49.5036.4835.69127.60122.184.44
Net Profit172.36153.6312.19670.83582.0115.26
CategoryQ1 FY26-27Q4 FY25-26Change %
Total Revenue2,149.771,847.7216.35
Expenses1,817.911,644.5610.54
Other Income15.3226.61-42.43
Operating Profit331.86203.1663.35
Depreciation97.7188.5910.29
Interest27.6122.5622.38
Profit Before Tax221.86118.6287.03
Tax49.50-82.91-159.70
Net Profit172.36201.53-14.47

Alembic Pharmaceuticals Ltd Research Reports

ActionTarget Price (₹)BrokerDateReports
Data Not Found

Alembic Pharmaceuticals Ltd Financial Reports

Data not available.

Alembic Pharmaceuticals Ltd Stock Prices Compare with Peers

Company1 Day1 Week1 Month3 Months6 Month1 Year
Alembic Pharma0.55%-0.29%3.01%7.56%9.38%-16.20%
OneSource Speci.-0.16%-1.12%-7.19%-15.18%15.96%-18.55%
Alivus Life-1.42%-3.22%22.43%28.68%52.43%38.84%
Concord Biotech-0.25%3.69%25.68%38.47%45.56%-8.54%
Shilpa Medicare-0.74%0.72%34.18%59.11%154.61%91.51%
Natco Pharma0.28%-0.81%-4.16%-24.75%-6.56%0.87%
Marksans Pharma0.53%-3.14%30.46%45.86%84.52%80.68%

Alembic Pharmaceuticals Ltd Corporate Information

Chairman and MD & CEO: Chirayu R Amin
Independent Director: Pranav N Parikh
Independent Director: K G Ramanathan
Independent Director: Paresh Saraiya
Director & CFO: Rajkumar Baheti
Independent Director: Milin Mehta
Managing Director: Pranav Amin
Managing Director: Shaunak Amin
Independent Director: Archana Hingorani
Company Secretary: Charandeep Singh Saluja

Alembic Pharmaceuticals Ltd News

No More Data

More